Page 2007 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 117 Transfusion Therapy for Coagulation Factor Deficiencies 1780.e1

REFERENCES 26. Fulcher CA, Zimmerman TS: Characterization of the human factor
VIII procoagulant protein with a heterologous precipitating antibody.
1. Cohn EJ, Strong LE, Hughes WJ, et al: Preparation and properties Proc Natl Acad Sci USA 79(5):1648–1652, 1982.
of serum and plasma proteins: IV. A system for the separation into 27. Horowitz B, Wiebe ME, Lippin A, et al: Inactivation of viruses in labile
fractions of the protein and lipoprotein components of biological tissues blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-
and fluids. J Am Chem Soc 68:459, 1946. butyl)phosphate detergent combinations. Transfusion 25(6):516–522,
2. Gilchrist GSPD, Roskos RR: Neurologic complications in hemophilia, 1985.
New York, 1989, Raven Press. 28. Horowitz B, Wiebe ME, Lippin A, et al: Inactivation of viruses in labile
3. Eyster ME, Gill FM, Blatt PM, et al: Central nervous system bleeding blood derivatives. II. Physical methods. Transfusion 25(6):523–527,
in hemophiliacs. Blood 51:1179, 1978. 1985.
4. Andes WA, Wulff K, Smith WB: Head trauma in hemophilia: a 29. Schwartz RS, Abildgaard CF, Aledort LM, et al: Human recombinant
prospective study. Arch Intern Med 144:1981, 1984. DNA-derived antihemophilic factor (factor VIII) in the treatment of
5. Bray GL, Luban NL: Hemophilia presenting with intracranial hem- hemophilia A. recombinant Factor VIII Study Group. N Engl J Med
orrhage: an approach to the infant with intracranial bleeding and 323(26):1800–1805, 1990.
coagulopathy. Am J Dis Child 141:1215, 1987. 30. Teitel J: Transmissible agents and the safety of coagulation factor
6. Schönlein J: Haemorrhaphilie (erbliche Anlage zu Blutungen) (vol 2). concentrates. World Federation of Hemophilia Facts and Figures 1, 1999.
Schönlein’s Vorlesungen niedergeschrieben und herausgegeben von 31. Roth DA, Kessler CM, Pasi KJ, et al: Human recombinant factor IX:
einem seiner Zuhörer. 1832. safety and efficacy studies in hemophilia B patients previously treated
7. Hopff F: Ueber die Haemophilie oder die erbliche Anlage zu toetlichen with plasma-derived factor IX concentrates. Blood 98(13):3600–3606,
Blutungen, Wuerzburg, 1828, CW Becker. 2001.
8. Lane S: Haemorrhagic diathesis: successful transfusion of blood. Lancet 32. Pool JG, Robinson J: Observations on plasma banking and transfu-
1:185, 1840. sion procedures for haemophilic patients using a quantitative assay for
9. Feissly R: Etudes sur l’hémophilie. Bull Mem Soc Med Hop Paris antihaemophilic globulin (AHG). Br J Haematol 24, 1959.
47:1923, 1778. 33. Wagner RBK, Penick G: Hemophilia and other hemorrhagic states.
10. Owen CBE: Infusion therapy in hemophilia A and B, New York, 1975, Other Hemorrhagic States, Chapel Hill, NC, 1959, University of North
American Elsevier Publishing Company. Carolina Press.
11. Weil P: L’hémophilie, pathogénie et sérothérapie. Presse Med 13:1905. 34. Aggeler PM, Spaet TH, Emery BB: Purification of plasma thromboplas-
12. Addis T: The pathogenesis of hereditary haemophilia. J Path Bac 15, tin factor B (plasma thromboplastin component) and its identification
1911. as a beta2 globulin. Science 119(3101):806, 1954.
13. Graham JB, Buckwalter JA, et al: Canine hemophilia; observations on 35. Schulman S, Wiechel B: Hepatitis, epidemiology and liver function in
the course, the clotting anomaly, and the effect of blood transfusions. hemophiliacs in Sweden. Acta Med Scand 215(3):249–256, 1984.
J Exp Med 90(2):97–111, 1949. 36. McDougal JS, Martin LS, Cort SP, et al: Thermal inactivation of the
14. Biggs R, Douglas AS, Macfarlane RG, et al: Christmas disease: a condi- acquired immunodeficiency syndrome virus, human T lymphotropic
tion previously mistaken for haemophilia. Br Med J 2(4799):1378–1382, virus-III/lymphadenopathy-associated virus, with special reference to
1952. antihemophilic factor. J Clin Invest 76(2):875–877, 1985.
15. Graham JB, Collins DL, Jr, Godwin ID, et al: Assay of plasma 37. Roberts HR: The treatment of hemophilia: past tragedy and future
antihemophilic activity in normal heterozygous (hemophilia) and promise. N Engl J Med 321(17):1188–1190, 1989.
prothrombinopenic dogs. Proc Soc Exp Biol Med 77(2):294–296, 1951. 38. Mannucci PM, Schimpf K, Abe T, et al: Low risk of viral infection after
16. Langdell RD, Wagner RH, Brinkhous KM: Effect of antihemophilic administration of vapor-heated factor VIII concentrate. International
factor on one-stage clotting tests; a presumptive test for hemophilia and Investigator Group. Transfusion 32(2):134–138, 1992.
a simple one-stage antihemophilic factor assy procedure. J Lab Clin Med 39. Gitschier J, Wood WI, Goralka TM, et al: Characterization of the
41(4):637–647, 1953. human factor VIII gene. Nature 312(5992):326–330, 1984.
17. Didisheim P, Loeb J, Blatrix C, et al: Preparation of a human plasma 40. Vehar GA, Keyt B, Eaton D, et al: Structure of human factor VIII.
fraction rich in prothrombin, proconvertin, Stuart factor, and PTC and Nature 312(5992):337–342, 1984.
a study of its activity and toxicity in rabbits and man. J Lab Clin Med 41. Yoshitake S, Schach BG, Foster DC, et al: Nucleotide sequence of
53(2):322–330, 1959. the gene for human factor IX (antihemophilic factor B). Biochemistry
18. Birk G: Zur Therapie der Hamophilie B. Klin Wschr 36:240, 1958. 24(14):3736–3750, 1985.
19. Pool JG, Shannon AE: Production of high-potency concentrates 42. Bray GL, Gomperts ED, Courter S, et al: A multicenter study of recom-
of antihemophilic globulin in a closed-bag system. N Engl J Med binant factor VIII (recombinate): safety, efficacy, and inhibitor risk in
273(27):1443–1447, 1965. previously untreated patients with hemophilia A. The Recombinate
20. Johnson A, et al: Two large-scale procedures for purification of human Study Group. Blood 83(9):2428–2435, 1994.
antihemophilic factor (AHF), abstracted. Blood 28:1011, 1966. 43. Lusher JM, Arkin S, Abildgaard CF, et al: Recombinant factor VIII
21. Brinkhous KM, Shanbrom E, Roberts HR, et al: A new high-potency for the treatment of previously untreated patients with hemophilia A.
glycine-precipitated antihemophilic factor (AHF) concentrate. Treat- Safety, efficacy, and development of inhibitors. Kogenate Previously
ment of classical hemophilia and hemophilia with inhibitors. JAMA Untreated Patient Study Group. N Engl J Med 328(7):453–459, 1993.
205(9):613–617, 1968. 44. White GC, 2nd, Courter S, Bray GL, et al: A multicenter study of
22. Hoag MS, Johnson FF, Robinson JA, et al: Treatment of hemophilia B recombinant factor VIII (Recombinate) in previously treated patients
with a new clotting-factor concentrate. N Engl J Med 280(11):581–586, with hemophilia A. The Recombinate Previously Treated Patient Study
1969. Group. Thromb Haemost 77(4):660–667, 1997.
23. Schimpf K, Mannucci PM, Kreutz W, et al: Absence of hepatitis after 45. Lee DC, Stenland CJ, Miller JL, et al: A direct relationship between the
treatment with a pasteurized factor VIII concentrate in patients with partitioning of the pathogenic prion protein and transmissible spon-
hemophilia and no previous transfusions. N Engl J Med 316(15):918– giform encephalopathy infectivity during the purification of plasma
922, 1987. proteins. Transfusion 41(4):449–455, 2001.
24. Schimpf K, Brackmann HH, Kreuz W, et al: Absence of anti-human 46. Will RG, Ironside JW, Zeidler M, et al: A new variant of Creutzfeldt-
immunodeficiency virus types 1 and 2 seroconversion after the treat- Jakob disease in the UK. Lancet 347(9006):921–925, 1996.
ment of hemophilia A or von Willebrand’s disease with pasteurized 47. Linnen J, Wages J, Jr, Zhang-Keck ZY, et al: Molecular cloning and
factor VIII concentrate. N Engl J Med 321(17):1148–1152, 1989. disease association of hepatitis G virus: a transfusion-transmissible
25. Fass DN, Knutson GJ, Katzmann JA: Monoclonal antibodies to porcine agent. Science 271(5248):505–508, 1996.
factor VIII coagulant and their use in the isolation of active coagulant 48. Nishizawa T, Okamoto H, Konishi K, et al: A novel DNA virus (TTV)
protein. Blood 59(3):594–600, 1982. associated with elevated transaminase levels in posttransfusion hepatitis